Loading…
Loading…
EQUITY / NASDAQ · XNCM
Mira Pharmaceuticals, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.7301 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.7301 USD · Volume 158,391
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Net income | -1,208,534 USD | -1,537,712 USD | — |
| Cash and cash equivalents | 3,609,442 USD | — | — |
| Total liabilities | 40,823 USD | — | — |
| Total equity | 8,162,317 USD | 569,859 USD | +1,332.34% |
| Total assets | 8,203,140 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,609,442 USD | — | — | 6,346,921 USD | 6,346,921 USD | 2,641,539 USD | — | — |
| Net incomeIncome statement | -1,208,534 USD | -2,358,686 USD | -1,150,152 USD | — | -10,442,485 USD | -1,137,673 USD | -4,459,164 USD | -1,537,712 USD |
| Total assetsBalance sheet | 8,203,140 USD | — | — | 11,093,605 USD | 11,093,605 USD | 7,633,280 USD | — | — |
| Total equityBalance sheet | 8,162,317 USD | — | 9,348,975 USD | 10,391,537 USD | 10,391,537 USD | 7,549,354 USD | — | 569,859 USD |
| Total liabilitiesBalance sheet | 40,823 USD | — | — | 702,068 USD | 702,068 USD | 83,926 USD | — | — |
| Financing cash flowCash flow statement | — | -330,607 USD | — | — | 8,175,659 USD | — | 3,335,240 USD | — |
| Operating cash flowCash flow statement | — | -2,406,872 USD | — | — | -4,661,669 USD | — | -3,526,632 USD | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.